This article first appeared on GuruFocus.
Cathie Wood’s Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical dollar amount of Alphabet (NASDAQ:GOOGL). The moves suggest Ark is becoming more selective inside artificial intelligence even as it increases exposure to speculative gene-editing companies and other high-growth themes.
Meta was Ark’s largest technology purchase, with the firm buying about 43,000 shares worth roughly $28 million. At the same time, Ark sold approximately 86,000 Alphabet shares valued at $28.6 million.
The trade does not necessarily signal a bearish view on Alphabet, since Ark frequently adjusts positions based on valuation and portfolio weightings. Still, the near dollar-for-dollar shift stands out because both companies are investing heavily in AI infrastructure and competing for investor attention around monetizing generative AI.
Ark also added more than 32,000 shares of AI-chip developer Cerebras Systems (NASDAQ:CBRS), worth about $6.5 million, while trimming Advanced Micro Devices (NASDAQ:AMD) by approximately $9.9 million and Palantir Technologies (NASDAQ:PLTR) by $6.5 million.
Biotechnology was another major focus. Ark bought more than 534,000 shares of Beam Therapeutics (NASDAQ:BEAM), worth roughly $14 million, alongside $8.5 million of CRISPR Therapeutics (NASDAQ:CRSP) and about $6 million of Intellia Therapeutics (NASDAQ:NTLA).
Elsewhere, Wood added Archer Aviation (NYSE:ACHR), Rocket Lab (NASDAQ:RKLB) and Robinhood Markets (NASDAQ:HOOD), while reducing exposure to Tempus AI (NASDAQ:TEM), Twist Bioscience (NASDAQ:TWST) and 10x Genomics (NASDAQ:TXG).
Investors Takeaway
Ark’s trading offers a useful snapshot of where Wood currently sees the best risk-reward, but investors should focus on the pattern rather than any single transaction.
The Meta-Alphabet rotation is particularly notable. Investors should watch whether Ark continues accumulating Meta while reducing Alphabet, which would make the shift more meaningful than a one-week rebalance.
For Ark’s gene-editing bets, upcoming clinical data remain the critical catalysts. Beam, CRISPR Therapeutics and Intellia can move sharply on trial results, regulatory updates and cash-burn expectations, making Ark’s aggressive buying potentially higher reward but considerably higher risk than its Meta purchase.
